Trial Profile
Phase 1/2a Clinical Study for Subjects With Rheumatoid Arthritis (RA) Using Multiple Dose Intravenous Infusions of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs)
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Adipose-derived autologous mesenchymal stem cell therapy-Celltex Therapeutics (Primary)
- Indications Osteoarthritis; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Celltex Therapeutics
- 13 Apr 2023 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 13 Apr 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 13 Apr 2023 Planned initiation date changed from 1 Dec 2022 to 1 Dec 2023.